Insmed, Inc. (NASDAQ:INSM) Position Decreased by Fourth Dimension Wealth LLC

Fourth Dimension Wealth LLC trimmed its position in Insmed, Inc. (NASDAQ:INSM) by 59.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,622 shares of the biopharmaceutical company’s stock after selling 2,399 shares during the quarter. Fourth Dimension Wealth LLC’s holdings in Insmed were worth $124,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in INSM. Darwin Global Management Ltd. lifted its position in shares of Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Norges Bank acquired a new position in Insmed during the fourth quarter valued at approximately $126,606,000. Vanguard Group Inc. grew its stake in shares of Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock worth $1,257,838,000 after acquiring an additional 1,075,796 shares during the last quarter. Brown Advisory Inc. acquired a new stake in shares of Insmed in the fourth quarter worth $45,773,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Insmed by 59.6% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company’s stock worth $113,748,000 after buying an additional 615,000 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have weighed in on INSM shares. Jefferies Financial Group reiterated a “buy” rating on shares of Insmed in a research note on Tuesday, June 10th. Leerink Partners lifted their price target on Insmed from $100.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, June 10th. Citigroup raised Insmed to a “buy” rating in a report on Tuesday, June 10th. UBS Group dropped their price objective on Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a report on Friday, May 9th. Finally, Royal Bank Of Canada boosted their price objective on Insmed from $99.00 to $106.00 and gave the stock an “outperform” rating in a report on Wednesday, June 11th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat, Insmed has an average rating of “Moderate Buy” and a consensus price target of $106.80.

Insmed Trading Up 2.7%

NASDAQ INSM opened at $105.42 on Tuesday. The stock has a market capitalization of $20.00 billion, a price-to-earnings ratio of -17.72 and a beta of 0.80. The stock’s 50 day moving average price is $75.49 and its two-hundred day moving average price is $74.73. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $107.91.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The company’s revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.06) EPS. As a group, analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 6,830 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $72.57, for a total value of $495,653.10. Following the sale, the chief executive officer now owns 233,924 shares in the company, valued at approximately $16,975,864.68. This represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Alexander Smith sold 409 shares of the company’s stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $65.61, for a total value of $26,834.49. Following the completion of the transaction, the insider now directly owns 91,794 shares in the company, valued at approximately $6,022,604.34. This represents a 0.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 430,987 shares of company stock worth $37,320,504 in the last 90 days. Corporate insiders own 3.00% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.